Robin Jackman
- Role
- Founder and CEO at Venquis Therapeutics
- Location
- San Diego, CA, US
- LinkedIn followers
- 500 followers
About Robin Jackman
Executive with 25+ years at intersection of medicine, business, finance, and…
Experience
Founder and CEO
Jan 2021 — Present
Chemically Targeted Mutant-selective Protein Degradation. Venquis Therapeutics has a platform to discover and develop mechanistically differentiated targeted small molecule direct protein degraders. Initial compounds target clinically relevant proteins in a mutant-selective fashion: degrading the driver-mutant proteins while sparing their corresponding endogenous wild-type proteins. This is a powerful approach for oncology and other therapeutic areas.
Education
Stanford University
B.S., Biology
Harvard Medical School
M.M.Sc., Medicine
Harvard University
Ph.D., Immunology
Skills
- Finance
- Pharmaceutical Industry
- Executive Management
- Biotechnology
- Life Sciences
- Oncology
- Mergers & Acquisitions
- Scientific Management
- Partnerships
- Clinical Development
- Investment Banking
- Drug Discovery
- Contract Negotiation
- Infectious Diseases
- Business Development
- Diagnostics
- Mergers
- Biomarkers
- Strategy
- Lifesciences
- Research and Development (R&D)
- Biopharmaceuticals
- Drug Development
- Corporate Development
- Clinical Trials
- Strategic Leadership
- Ip Development
- R&D
- Start-Ups
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.